Dodecene, hydroformylation products, low-boiling

Endpoint summary

Additional information

AMES test:

Introduction. Method conform the guidelines for bacterial mutagenicity testing published by the major Japanese Regulatory Authorities including METI, MHLW and MAFF. It also meets the requirements of the OECD Guidelines for Testing of Chemicals No. 471 "Bacterial Reverse Mutation Test", Method B13/14 of Commission Regulation (EC) Number 440/2008 of 30 May 2008 and the USA, EPA (TSCA) OPPTS harmonised guidelines.

Methods. Salmonella typhimuriumstrains TA1535, TA1537, TA98, TA100 andEscherichia colistrain WP2uvrAwere treated with the test material using the Ames plate incorporation method at five dose levels, in triplicate, both with and without the addition of a rat liver homogenate metabolising system (10% liver S9 in standard co-factors). The dose range was determined in a preliminary toxicity assay and was 50 to 5000 µg/plate in the first experiment. The experiment was repeated on a separate day using the same dose range as Experiment 1, fresh cultures of the bacterial strains and fresh test material formulations. 

Results. The vehicle (acetone) control plates gave counts of revertant colonies within the normal range. All of the positive control chemicals used in the test induced marked increases in the frequency of revertant colonies, both with or without metabolic activation. Thus, the sensitivity of the assay and the efficacy of the S9-mix were validated.

The test material caused no visible reduction in the growth of the bacterial background lawn at any dose level and was, therefore, tested up to the maximum recommended dose level of 5000 µg/plate. A fine, particulate precipitate was observed at and above 1500 µg/plate, this observation did not prevent the scoring of revertant colonies.

No significant increases in the frequency of revertant colonies were recorded for any of the bacterial strains, with any dose of the test material, either with or without metabolic activation.

Conclusion. The test material was considered to be non-mutagenic under the conditions of this test.

Chromosome aberration test:

A chromosome aberration study with Oxooil LS13 was performed according to OECD 473 guideline and GLP principles, in cultured peripheral human lymphocytes in two independent experiments. The test substance was tested up to and beyond precipitating concentrations. Both in the absence and presence of S9-mix, Oxooil LS13 did not induce a statistically significant or biologically relevant increase in the number of cells with chromosome aberrations. No effects of Oxooil LS13 on the number of polyploid cells and cells with endoreduplicated chromosomes were observed both in the absence and presence of S9-mix.

It can be concluded that Oxooil LS13 does not disturb mitotic processes and cell cycle progression and does not induce numerical chromosome aberrations under the experimental conditions described in this report.

MLA assay:

A mouse lymphoma assay was conducted according to OECD 476 guideline and GLP principles. The spontaneous mutation frequencies in the solvent-treated control cultures were between the minimum and maximum value of the historical control data range. Positive control chemicals, methyl methane sulfonate and cyclophosphamide induced appropriate responses. Oxooil LS13 was tested up to and including precipitating and/or cytotoxic concentrations. Cytotoxicity was observed with and without metabolic activation.

In the absence of S9-mix, Oxooil LS13 did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent repeat experiment with modifications in the duration of treatment time. In the presence of 8% v/v S9-mix, Oxooil LS13 did not induce a significant increase in the mutation frequency in the first experiment. This result was confirmed in an independent repeat experiment with 12% v/v S9 for metabolic activation. It is concluded that Oxooil LS13 is not mutagenic in the mouse lymphoma L5178Y test system under the experimental conditions described in this report.

Justification for selection of genetic toxicity endpoint
No study was selected, since all three in vitro studies were negative.

Short description of key information:
Three in vitro tests were performed (AMES test, chromosome aberration test and MLA assay). Oxooil LS13 was shown to be negative with and without metabolic activation in all tests, therefore Oxooil LS13 is considered not to be genotoxic.

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the available data, Oxooil LS13 is not classified for genotoxicity according to CLP Regulation (EC) No. 1272/2008.